Previous Close | 49.2 |
1-Year Change | -38.62% |
6-Months Change | -8.11% |
3-Months Change | -11.35% |
Moving Avg (50d) | 48.821 |
Moving Avg (200d) | 54.104 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.73M |
Beta (3-Years) | 1.05 |
Revenue Growth (ttm) | -94.73% |
Net Profit Margin (ttm) | -6739.96% |
Return On Assets (ttm) | -71.12% |
EPS (ttm) | -5599.57 |
PE Ratio (ttm) | -0.01 |
Dividend Yield | % |
Asset Description: | Cytokinetics, Incorporated |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-29 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
50.184 | 51.66 | 52.644 | 54.12 | 56.58 | 59.04 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.